ISBN:  Unavailable

Category: Unavailable

Page count: 122

Background: Endothelial dysfunction manifested by diminished flow-mediated dilation (FMD) of brachial artery has been shown to improve after treatment with several lipolytics in patients with hypercholesterolemia. However, there is no data of the effects of cerivastatin, new HMG-CoA reductase inhibitor andfibric acid derivate fenofibrate on the endothelial dysfunction in subjectswith combined hyperlipidemia. Subjects and methodsČ Forty middle-aged males with combined hyperlipidemia with no other atherogenic risk factors wererandomised, after 6 week run-in phase with AHA step I diet treatment, to 12 week treatment either with fenofibrate (250 mg daily) or cerivastatin. Cerivastatin was given in daily dose of 0,2 mg for 6 weeks and was increased to 0,4 mg daily in 10 patients, who did not achieve LDL-cholesterol goal of